WBDE(SZ:002082)2021-08-26 16:00Financial Performance - The company's operating revenue for the first half of 2021 was ¥928,668,326.21, a decrease of 86.13% compared to ¥6,695,684,676.46 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2021 was ¥112,253,691.84, down 6.90% from ¥120,574,677.87 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥89,541,786.57, a decline of 21.72% compared to ¥114,389,819.07 in the same period last year[21]. - The company reported a basic earnings per share of ¥0.18, down 10.00% from ¥0.20 in the previous year[21]. - The company reported a total revenue of 1.2 billion RMB for the first half of 2021, representing a year-on-year increase of 15%[108]. - The company reported a total of 13.51 billion yuan in cash from the sale of 100% equity in Huzhou Dongliang Aluminum Industry Co., Ltd., which will be used for new drug research and project construction[132]. - The company reported a net loss attributable to shareholders of CNY -122,855,025.80, indicating a significant decrease in profitability compared to the previous period[194]. - The total revenue for the period reached CNY 2,807,341,714.55, showing a decrease of CNY 34,435,859.29 compared to the previous period[199]. Cash Flow and Assets - The net cash flow from operating activities improved to -¥119,678,340.56, a 25.39% increase from -¥160,401,209.28 in the previous year[21]. - The total assets at the end of the reporting period were ¥4,046,656,425.71, a decrease of 28.53% from ¥5,662,314,950.96 at the end of the previous year[21]. - The company's current assets totaled CNY 2,199,331,456.79, down from CNY 3,081,954,850.43 at the end of 2020, indicating a decrease of about 28.6%[168]. - Cash and cash equivalents decreased significantly from CNY 574,183,019.64 at the end of 2020 to CNY 185,201,417.14, a reduction of approximately 67.7%[167]. - The total cash and cash equivalents decreased by 335,338,992.02 CNY in the first half of 2021[186]. Business Strategy and Operations - The company plans not to distribute cash dividends or issue bonus shares[6]. - The significant fluctuation in operating data is primarily due to the divestment of the aluminum processing business and the cessation of the Xindong Aluminum trading business[21]. - The company completed the divestiture of its traditional aluminum processing business on March 1, 2021, successfully transitioning to the pharmaceutical manufacturing industry[28]. - The company is committed to expanding its pharmaceutical product line and enhancing its market presence through strategic innovations and product development[28]. - The company has halted operations of its subsidiary Shanghai Xingdong Aluminum Trading since Q1 2021, focusing solely on the pharmaceutical sector[28]. - The company has optimized its business structure by divesting non-pharmaceutical operations, enhancing the synergy between its pharmaceutical manufacturing and medical device segments[49]. Research and Development - The company has developed innovative products such as Huperzine A, which is effective for cognitive function improvement and memory disorders, and has received national awards[28]. - Wanbangde Pharmaceutical has established a comprehensive R&D system with 32 authorized patents, including 25 invention patents, and multiple new drug research projects in various clinical stages[44]. - The company plans to improve its R&D system and accelerate the development and registration of strategic new products to meet market demands[49]. - The company is currently conducting clinical trials for the new drug "Shishan Jianjia Controlled Release Tablets" and has initiated the II phase clinical plan[35]. Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2022 through strategic partnerships and local collaborations[60]. - The company aims to leverage its sales network in South Africa to actively expand its international market presence[64]. - The company is actively pursuing FDA 510K certification for its self-owned brand of syringes to enter the international market[39]. Environmental Compliance - The company has established a dedicated environmental protection department and strictly adheres to national environmental regulations in its production processes[93]. - The company reported no instances of exceeding pollution discharge standards in its wastewater management[100]. - The company is committed to environmental compliance and sustainability in its operations[106]. - The company has implemented new strategies for waste management and environmental compliance, reflecting its focus on sustainability and regulatory adherence[103]. Shareholder and Governance - The company emphasizes shareholder rights protection, ensuring compliance with legal procedures for shareholder meetings and providing online voting platforms[118]. - There were no changes in the company's board of directors, supervisors, or senior management during the reporting period[96]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[122].